Albireo (NASDAQ:ALBO) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.75 by ($3.90), MarketWatch Earnings reports. The firm had revenue of $11.20 million for the quarter, compared to analyst estimates of $55.33 million.
Albireo opened at $32.86 on Friday, MarketBeat Ratings reports. Albireo has a 52 week low of $15.31 and a 52 week high of $39.87.
A number of analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Albireo from a “hold” rating to a “sell” rating in a research report on Wednesday, January 24th. BidaskClub raised shares of Albireo from a “hold” rating to a “buy” rating in a research report on Tuesday, March 20th. ValuEngine raised shares of Albireo from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Needham & Company LLC assumed coverage on shares of Albireo in a research report on Thursday, March 15th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and issued a $63.00 price target on shares of Albireo in a research report on Wednesday, March 28th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $57.60.
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis.
Receive News & Ratings for Albireo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo and related companies with MarketBeat.com's FREE daily email newsletter.